New research and development

Current tuberculosis (TB)-control methods, which do not include an adequate vaccine, do not effectively block transmission of TB.  Modelling studies show that mass vaccination campaigns using new vaccines could prevent 85.9 million new cases and 14.5 million deaths from 2015 through 2050 in southern Asia alone. After a dearth of many years, the development pipeline now includes 7 vaccine candidates that are being tested in humans. Two nonreplicating viral vectored vaccines have very recently entered the first phase IIb efficacy trial in infants (the first such trial in 80 years) and in human immunodeficiency virus-infected adults. Science is moving forward, but the scientific advancements need to be accompanied by political mobilization to ensure that the resources are available to develop, manufacture, and distribute the new vaccines and, thus, save millions of lives.

  • Improved TB therapy
  • TB drug clinical development
  • Challenges for drug development

Related Conference of New research and development

March 17-18, 2025

54th World Congress on Microbiology

Berlin, Germany
July 28-29, 2025

17th International Virology Summit

Paris, France
August 25-26, 2025

6th International Conference on Molecular Microbiology

Singapore City, Singapore
September 22-23, 2025

13th World Congress and Expo on Applied Microbiology

Dubai, UAE

New research and development Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in